Dr. Lal PathLabs Limited (BOM:539524)
India · Delayed Price · Currency is INR 1,692.85
+8.60 (0.51%)
At close: Jul 10, 2026
Dr. Lal PathLabs Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, Dr. Lal PathLabs stock has a consensus rating of "Buy" and an average price target of ₹1,686. The average 1-year stock price forecast is 0.40% lower than the current stock price, while the lowest is ₹1,180 (-30.30%) and the highest is ₹2,072 (+22.40%).
Price Target: ₹1,686 (-0.40%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Dr. Lal PathLabs stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 12 | 13 | 13 | 17 | 17 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 2 | 3 | 2 | 1 | 1 |
| Sell | 1 | 2 | 2 | 2 | 1 | 1 |
| Strong Sell | 5 | 4 | 2 | 2 | 2 | 2 |
| Total | 26 | 25 | 25 | 24 | 26 | 26 |
Financial Forecast
Revenue This Year
31.38B
from 27.63B
Increased by 13.59%
Revenue Next Year
35.52B
from 31.38B
Increased by 13.18%
EPS This Year
35.35
from 30.40
Increased by 16.29%
EPS Next Year
41.25
from 35.35
Increased by 16.69%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 31.6B | ||
| Avg | 31.4B | ||
| Low | 31.0B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 14.5% | ||
| Avg | 13.6% | ||
| Low | 12.2% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 38.00 | ||
| Avg | 35.35 | ||
| Low | 33.40 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 25.0% | ||
| Avg | 16.3% | ||
| Low | 9.9% |